Domestic Sales of GMP-Grade mRNA and Lipid Nanoparticles
First written in FY2024-Q1. 3 of 4 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「In June 2023, we entered into an exclusive distributorship agreement for Japan with Vernal Biosciences (Vermont, USA) and began selling GMP-grade mRNA and lipid nanoparticles.」
The company has reaffirmed its policy of supplying GMP-grade mRNA and lipid nanoparticles to pharmaceutical companies in Japan under its exclusive distributorship agreement with Vernal Biosciences. - FY2024-Q3RestatedAnnual report
「In June 2023, we entered into an exclusive distributorship agreement for Japan with Vernal Biosciences (Vermont, USA) and began selling GMP-grade mRNA and lipid nanoparticles.」
The company has reaffirmed its policy of supplying GMP-grade mRNA and lipid nanoparticles to pharmaceutical companies in Japan under its exclusive distributorship agreement with Vernal Biosciences. - FY2024-Q2RestatedAnnual report
「In June 2023, we entered into an exclusive distributorship agreement for Japan with Vernal Biosciences (Vermont, USA) and began selling GMP-grade mRNA and lipid nanoparticles.」
The company has reaffirmed its policy of supplying GMP-grade mRNA and lipid nanoparticles to pharmaceutical companies in Japan under its exclusive distributorship agreement with Vernal Biosciences. - FY2024-Q1First statedAnnual report
「In June 2023, we entered into an exclusive distributorship agreement for Japan with Vernal Biosciences (Vermont, USA) and began selling GMP-grade mRNA and lipid nanoparticles. mRNA is expected to have broad applications, including cancer therapeutics and vaccines, and we aim to supply it to pharmaceutical companies in Japan.」
The company has disclosed a new research support business under which it entered into an exclusive distributorship agreement with Vernal Biosciences for Japan and began selling GMP-grade mRNA and lipid nanoparticles.